Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206866 | 0.93 | OPRM1 (0.49) | ACHEOPRM1OPRK1OPRD1ALDH1A1 | |
| SCHEMBL4728528 | 0.82 | ALOX5 (0.45) | ACHEALOX5 | |
| SCHEMBL8777957 | 0.79 | LMNA (0.48) | ACHEOPRM1OPRK1OPRD1MAPT | |
| SCHEMBL8777946 | 0.78 | MAPT (0.41) | ACHEALDH1A1GAAMAPTTSHR | |
| SCHEMBL9205594 | 0.78 | MTNR1A (0.40) | OPRM1OPRK1OPRD1ALDH1A1ALOX5 | |
| SCHEMBL9029836 | 0.78 | HDAC1 (0.53) | ACHEALDH1A1GAAMAPTCASP1 | |
| SCHEMBL9597526 | 0.76 | ALDH1A1 (0.51) | ACHEALDH1A1HPGDGAAMAPT | |
| SCHEMBL9088235 | 0.76 | LMNA (0.37) | MAPTALOX5TP53 | |
| SCHEMBL9597418 | 0.74 | HDAC1 (0.45) | OPRM1OPRK1OPRD1ALDH1A1HPGD | |
| SCHEMBL9206959 | 0.74 | MAPT (0.49) | ALDH1A1HPGDGAAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0651743-B1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1997-12-17 | — | — | EP | claimed |
| US-5541218-A | Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors | PFIZER INC. (US) | 1996-07-30 | — | — | US | claimed |
| EP-0651743-A1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002459-A1 | INDOLINYL N-HYDROZYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-02-03 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-5541218-A | Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors | PFIZER INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0651743-A1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002459-A1 | INDOLINYL N-HYDROZYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ACHE 16/4885OPRM1 3844/4885OPRK1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.